30-Second Takeaway
- Pembrolizumab plus gemcitabine-based hypofractionated chemoradiation achieves promising bladder-intact control with acceptable toxicity in muscle-invasive disease.
- Darolutamide prolongs control of metastatic hormone-sensitive prostate cancer while maintaining higher quality of life than placebo.
- Digital Uromonitor improves non–muscle-invasive bladder cancer surveillance accuracy over cytology and earlier qPCR assay, with strong negative predictive value.
Week ending April 11, 2026
Concise updates in bladder preservation, systemic GU therapies, and emerging biomarkers
Pembrolizumab-augmented trimodality therapy yields durable bladder-intact control in MIBC
In this multicenter phase 2 trial, 54 MIBC patients received pembrolizumab plus low-dose gemcitabine and hypofractionated radiation after maximal TURBT. Among 48 patients in the efficacy cohort, 67% had clinical T2 disease, reflecting typical trimodality candidates. Two-year bladder-intact disease-free survival was 60%, with 2-year metastasis-free and overall survival of 81% and 83%, respectively. Grade ≥3 treatment-related adverse events occurred in 25%, suggesting acceptable toxicity for fit patients. Efficacy appeared comparable to historical trimodality therapy, but the single-arm design and modest sample size limit definitive comparisons.
Darolutamide maintains QoL and delays progression in metastatic hormone-sensitive prostate cancer
This pooled analysis from ARASENS and ARANOTE linked longitudinal quality-of-life trajectories with disease progression in metastatic hormone-sensitive prostate cancer. Patients on darolutamide maintained higher QoL versus placebo across triplet and doublet treatment backbones. QoL decline meeting the minimally important difference was associated with higher castration resistance or death risk and shorter radiologic progression-free survival. Higher baseline FACT-P QoL was associated with improved radiologic progression-free survival in ARANOTE, but not clearly with NCCN-FACT FPSI-17 in ARASENS. Joint modeling suggested darolutamide’s benefit was driven mainly by a direct effect, with a smaller component mediated through preserved QoL.
ISUP provides updated framework for genitourinary cancer precursor lesions
The ISUP Florence Consensus Conference establishes contemporary definitions for genitourinary cancer precursor lesions across prostate, bladder, kidney, testis, and penis. Recommendations emphasize standardized terminology and reporting to improve communication between pathologists and urologists. The document links precursor entities with their malignant potential to better inform surveillance intensity and timing of intervention. It also defines research priorities to refine risk estimates and management of premalignant genitourinary conditions.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.